End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T‐cell acute lymphoblastic leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|11|2040-2043

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.11, 2015-11, pp. : 2040-2043

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T‐cell acute lymphoblastic leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 2040-2043

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunological Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 442-448

Karger

Access to resources Recommend Favorite

Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Current Status and Challenges

By  

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1656-1660

John Wiley & Sons Inc

Access to resources Recommend Favorite